Interventional Radiology Unit, Radiology Service, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Radiology Service, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
Actas Urol Esp (Engl Ed). 2024 Mar;48(2):155-161. doi: 10.1016/j.acuroe.2023.10.006. Epub 2023 Oct 11.
Due to their increasing prevalence and complex management, renal tumors are challenging for health professionals. The study aims to evaluate the usefulness of R.E.N.A.L. and PADUA nephrometry scores in the prediction of complications after percutaneous cryoablation.
The study prospectively analyzed 90 patients with 101 stage T1a renal cell carcinoma (RCC) tumors treated with cryoablation.
Ninety patients with 101 small renal tumors who received cryoablative therapy were investigated. The mean age of the patients was 68 years and 74.4% were male. Most tumors were smaller than 4 cm (89.1%) and the mean PADUA and R.E.N.A.L. scores were 8.65 and 7.35, respectively. Complications were observed in 12 cases. PADUA and R.E.N.A.L. scores demonstrated moderate predictive power (AUC = 0.58 and AUC = 0.63, respectively) for post-cryoablation complications.
Percutaneous cryoablation is a safe and effective treatment for small renal tumors. The R.E.N.A.L. and PADUA renal nephrometry scores have moderate predictive power for complications associated with percutaneous cryoablation of renal tumors.
由于其发病率的增加和复杂的管理，肾脏肿瘤对医疗专业人员来说是一个挑战。本研究旨在评估 R.E.N.A.L. 和 PADUA 肾脏肿瘤测量评分在预测经皮冷冻消融术后并发症中的作用。
本研究前瞻性分析了 90 例 101 例 T1a 期肾细胞癌（RCC）肿瘤患者接受冷冻消融治疗的情况。
对 90 例接受冷冻消融治疗的 101 例小肾癌患者进行了调查。患者的平均年龄为 68 岁，74.4%为男性。大多数肿瘤小于 4cm（89.1%），平均 PADUA 和 R.E.N.A.L. 评分分别为 8.65 和 7.35。12 例出现并发症。PADUA 和 R.E.N.A.L. 评分对冷冻消融术后并发症具有中等预测能力（AUC 分别为 0.58 和 0.63）。
经皮冷冻消融术是治疗小肾癌的一种安全有效的方法。R.E.N.A.L. 和 PADUA 肾脏肿瘤测量评分对经皮冷冻消融治疗肾肿瘤相关并发症具有中等预测能力。
